FDA Approves Lipfendra (enlicitide) Oral PCSK9 Inhibitor to Reduce LDL-C in Adults with Hypercholesterolemia
RegulatoryapprovedLipfendraPositive
AI Analysis
Summary
Merck announced FDA approval of Lipfendra (enlicitide), an oral PCSK9 inhibitor tablet for reducing LDL cholesterol in adults with hypercholesterolemia. This represents a significant regulatory milestone for the company's cardiovascular portfolio.
Outcome Details
FDA approved Lipfendra (enlicitide) oral PCSK9 inhibitor tablets 20 mg
Importance:9/10
Sentiment:
0.90
FDA approvalPCSK9 inhibitorcardiovascularhypercholesterolemiaoral formulation
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on July 16, 2026 9:07 PM